中文
  • News release
  • /
  • In brief
CFDA Granted Approval of Phase I-III ...
Clinical Trials of Sirotinib (XZP - 5491) by CFDA...
CFDA Granted Approval of Phase II/III...
Phase II/ III Clinical Trials of Imigliptin Hydr...
CFDA Granted Approval of Phase I-III ...
Clinical Trials of Sirotinib (XZP - 5491) by CFDA...
CFDA Granted Approval of Phase II/III...
Phase II/ III Clinical Trials of Imigliptin Hydr...
XuanZhu Pharma Co., Ltd. is an international research and development (R&D) enterprise of innovative drugs. Founded in 2002 with the registered capital of 50 million yuan，XuanZhu Pharma is focused on R&D of new chemical entities. It is a wholly-owned subsidiary and innovative drug research institute of Sihuan Pharmaceutical Holdings Group Ltd (Sihuan Pharma). Sihuan Pharma, listed in Hong Kong (stock code: 00460.HK) on October 28, 2010, has developed into a multi-functional pharmaceutical group company, covering ...
资质荣誉
  • 发展历程
  • /
  • 研发平台
2018 2017 2016 2015
CFDA Granted Approval of Phase I to III Clinical Trials for XZP-3287，a Category 1.1 Innovative Drug
CFDA Granted Approval of Phase II/III Clinical Trials for Imigliptin Hydrochloride，a category 1.1 antidiabetic drug
The injectable antibiotic Benapenem, National Category 1.1 new drug, is tested on human for the first time. It is well tolerated in subjects；Covance and XuanZhu Pharma announce partnership for preclinical and clinical portfolio development；FPI is achieved in the US for Pirotinib, National Category 1.1 anti-cancer new drug；The IND of national Category 1.1 anti-oncology new drug Sirotinib is approved by CFDA；CFDA granted IND applications to Pirotinib Hydrochloride, a category 1.1 anti-oncology drug.
2018 2017 2016 2015
CFDA Granted Approval of Phase I to III Clinical Trials for XZP-3287，a Category 1.1 Innovative Drug
CFDA Granted Approval of Phase II/III Clinical Trials for Imigliptin Hydrochloride，a category 1.1 antidiabetic drug
The injectable antibiotic Benapenem, National Category 1.1 new drug, is tested on human for the first time. It is well tolerated in subjects；Covance and XuanZhu Pharma announce partnership for preclinical and clinical portfolio development；FPI is achieved in the US for Pirotinib, National Category 1.1 anti-cancer new drug；The IND of national Category 1.1 anti-oncology new drug Sirotinib is approved by CFDA；CFDA granted IND applications to Pirotinib Hydrochloride, a category 1.1 anti-oncology drug.
Project Management The New Drug Design and Synthesis Center Center for Bacteriology Center for Pharmacokinetics and Drug Metabolism Center for in vivo Pharmacology Center for Early Safety Assessment The Screening and Characterization Center of API Crystal Forms and Salt Forms API Scale-Up Center Formulation and Preformulation Analysis Center International Clinical Research Centers Patent matters 策划市场中心 BD商务开发与合作中心 注册法规中心 处方前研发中心

Email | Terms of Use | Contact us

2014版权©轩竹医药科技有限公司保留所有权利 鲁ICP备09030169号